501693-47-6

Usage

Molecular weight

238.24 g/mol

Derivative of

furo[2,3-d]pyrimidin-4-amine

Contains

fused pyrimidine and furan ring system

Functional group

aminophenyl group

Potential applications

medicinal chemistry and pharmaceutical research

Potential uses

drug design and development

Further research needed

to explore pharmacological properties and therapeutic uses

Upstream product

• 2719-21-3 4-(N-acetylamino)acetophenone 
• 606099-87-0 5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-amine 
• 7439-89-6 iron 
• 65921-30-4 2-(4-nitrophenyl)-2-oxoethyl acetate 
• 99-81-0 4-Nitrophenacyl bromide 
• 100-19-6 (4-nitrophenyl)ethanone 
• 3473-63-0 formamidine acetic acid 
• 62830-97-1 2-(4-aminophenyl)-2-oxoethyl acetate 
• 501696-51-1 4'-acetamido-2-hydroxyacetophenone 
• 501696-53-3 4-(4-acetamidophenyl)-3-cyano-2-[(ethoxymethylidene)amino]furan 
• 501696-52-2 N-[4-(5-amino-4-cyano-furan-3-yl)-phenyl]-acetamide 
• 501693-44-3 4-amino-5-(4-acetamidophenyl)-furo[2,3-d]pyrimidine 
• 21675-02-5 4-acetylaminophenacyl bromide 
• 606099-85-8 2-amino-4-(4-nitrophenyl)furan-3-carbonitrile 

Relevant academic research and scientific papers

A process for preparing 4-amino-3 - (4-aminophenyl) furo [2,3-d] pyrimidine method

The invention discloses a method for preparing 4-amino-3-(4-aminobenzene)furo[2,3-d] pyrimidine. The method comprises the following steps: using nitroacetophenone as a raw material, reacting the nitroacetophenone and N-bromo-succinimide to generate 2-brom

Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis

Potent inhibitors of RIP1 kinase from three distinct series, 1-aminoisoquinolines, pyrrolo[2,3-b]pyridines, and furo[2,3-d]pyrimidines, all of the type II class recognizing a DLG-out inactive conformation, were identified from screening of our in-house ki

Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2

During our effort to develop dual VEGFR2 and Tie-2 inhibitors as anti-angiogenic agents for cancer therapy, we discovered 4-amino-5-(4-((2-fluoro-5-(trifluoromethyl)phenyl)- aminocarbonylamino)phenyl)furo[2,3-d]pyrimidine (8a) possessing strong inhibitory activity at both the enzyme and cellular level against VEGFR2 and Tie-2. Compound 8a demonstrated high pharmacokinetic exposure through oral administration, and showed marked tumor growth inhibition and anti-angiogenic activity in mouse HT-29 xenograft model via once-daily oral administration.

Kinase inhibitors

The present application is directed to pyrazolopyrimidine and furopyrimnidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

Kinase inhibitors

The present application is directed to pyrazolopyrirnidine and furopyrimidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.